Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Portal
United States
- Watertown, Massachusetts
- 20/03/2024
- Pre-Seed
- $5,000,000
Portal is a cell engineering platform company focused on enabling next generation cell engineering and cell analytics across research and clinical applications. We are implementing a simplified approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and AI-driven technologies. Portal’s initial product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types. The technology's ability to be used stand-alone or as an integrated component of third-party systems provides a significant opportunity to broadly impact the fields of biological research and cellular therapeutics
- Industry Biotechnology Research
- Website https://portal.bio/
- LinkedIn https://www.linkedin.com/company/portal-bio/
Related People
Armon Sharei, PhDFounder
United States -
Arlington, Massachusetts
Armon Sharei, PhD, is the Chief Executive Officer and Founder of SQZ Biotech, a biotechnology company creating innovative treatments by transforming cells into sophisticated therapeutics. Utilizing the proprietary Cell Squeeze® technology to develop a new generation of cell therapies, SQZ is creating powerful, multifunctional cell therapies for a range of diseases, with an initial focus on cancer, infectious disease and autoimmune disease.
Dr. Sharei developed the Cell Squeeze® platform during his PhD work in chemical engineering at MIT.
After his PhD, Dr. Sharei was a Ragon Institute postdoctoral Fellow at Harvard Medical School. He is co-author of 18 peer-reviewed publications and inventor on over 20 patents. In 2013, he founded SQZ Biotech. As a leader, Dr. Sharei’s motivating factor for his company is to simply make the world a better place. Dr. Sharei is driven by the potential global patient impact of the novel cell therapies SQZ can create using its breakthrough technology.
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)